Truist Financial’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Truist Financial’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-20,000	Closed	-$63K	–	2901
2021 Q4	$63K	Hold	20,000	–	–	﹤0.01%	2696
2021 Q3	$65K	Hold	20,000	–	–	﹤0.01%	2657
2021 Q2	$75K	Hold	20,000	–	–	﹤0.01%	2662
2021 Q1	$100K	Sell	20,000 -13,000	-39%	-$105K	﹤0.01%	2575
2020 Q4	$417K	Sell	33,000 -2,740	-8%	-$31.2K	﹤0.01%	1948
2020 Q3	$351K	Hold	35,740	–	–	﹤0.01%	1924
2020 Q2	$356K	Hold	35,740	–	–	﹤0.01%	1829
2020 Q1	$316K	Buy	35,740 +10,000	+39%	+$98.6K	﹤0.01%	1824
2019 Q4	$237K	Buy	+25,740	New	+$182K	﹤0.01%	2282

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Truist Financial's CNCE Position: Q1 2022 in Review

Truist Financial sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2022, closing a stake of 20,000 shares — an estimated $63K sold.

Truist Financial first reported a position in CNCE in Q4 2019 and held it in 9 quarters. The position peaked at $417K in Q4 2020. 53 funds tracked by Wall St. Rank hold CNCE as of Q1 2022.

Truist Financial reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Truist Financial sold 20,000 Concert Pharmaceuticals, Inc. shares in Q1 2022, an estimated $63K.
Truist Financial first reported a position in Concert Pharmaceuticals, Inc. in Q4 2019 and held it in 9 quarters.
Truist Financial's Concert Pharmaceuticals, Inc. position peaked at $417K in Q4 2020.
53 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2022.

Based on Truist Financial's 13F filing for Q1 2022, filed 22 Apr 2022.